| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
381,510,000 |
| Market
Cap: |
169.20(M) |
| Last
Volume: |
4,513,016 |
Avg
Vol: |
4,500,422 |
| 52
Week Range: |
$0.4435 - $2.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Agenus is a clinical-stage immuno-oncology (I-O) company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer and infections. Co.'s antibody candidates are balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody), which are in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Co. is also developing an anti-CTLA-4 antibody, botensilimab (also known as AGEN1181), which is designed to improve the magnitude of responses to first-generation anti-CTLA-4 molecules.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
500,000 |
525,000 |
525,000 |
525,000 |
| Total Buy Value |
$324,050 |
$343,050 |
$343,050 |
$343,050 |
| Total People Bought |
1 |
2 |
2 |
2 |
| Total Buy Transactions |
1 |
2 |
2 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Armen Garo H |
Chairman and CEO |
• • – |
2021-03-26 |
4 |
A |
$2.85 |
$11,904 |
D/D |
4,177 |
449,922 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2021-03-12 |
4 |
A |
$3.31 |
$11,347 |
D/D |
3,428 |
445,745 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2021-02-26 |
4 |
A |
$4.00 |
$11,344 |
D/D |
2,836 |
442,317 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2021-02-12 |
4 |
A |
$4.64 |
$11,345 |
D/D |
2,445 |
439,481 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2021-01-29 |
4 |
A |
$3.68 |
$11,345 |
D/D |
3,083 |
437,036 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2021-01-15 |
4 |
A |
$3.35 |
$11,343 |
D/D |
3,386 |
433,953 |
|
- |
|
| Hirsch Susan B |
Director |
– • – |
2021-01-04 |
4 |
A |
$3.78 |
$13,748 |
D/D |
3,637 |
3,637 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2020-12-31 |
4/A |
A |
$3.18 |
$14,870 |
D/D |
4,676 |
430,567 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2020-12-18 |
4 |
A |
$3.55 |
$14,779 |
D/D |
4,163 |
421,845 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2020-11-20 |
4 |
A |
$3.65 |
$14,779 |
D/D |
4,049 |
412,645 |
|
- |
|
| Armen Garo H |
Director |
– • – |
2020-11-06 |
4 |
A |
$3.82 |
$14,780 |
D/D |
3,869 |
343,496 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2020-10-23 |
4 |
A |
$3.94 |
$14,779 |
D/D |
3,751 |
339,627 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2020-10-09 |
4 |
A |
$4.35 |
$14,777 |
D/D |
3,397 |
335,876 |
|
- |
|
| Hirsch Susan B |
Director |
– • – |
2020-10-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
55,750 |
|
2% |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2020-09-25 |
4 |
A |
$4.02 |
$14,778 |
D/D |
3,676 |
332,479 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2020-09-11 |
4 |
A |
$4.99 |
$14,780 |
D/D |
2,962 |
328,803 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2020-08-28 |
4 |
A |
$4.28 |
$14,775 |
D/D |
3,452 |
325,841 |
|
- |
|
| Clark Paul N |
Director |
– • – |
2020-08-27 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
70,805 |
|
-19% |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2020-08-14 |
4 |
A |
$3.71 |
$14,781 |
D/D |
3,984 |
322,389 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2020-07-31 |
4 |
A |
$3.04 |
$14,777 |
D/D |
4,861 |
318,405 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2020-07-17 |
4 |
A |
$3.60 |
$14,778 |
D/D |
4,105 |
313,544 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• • – |
2020-07-02 |
4 |
A |
$4.02 |
$14,778 |
D/D |
3,676 |
309,439 |
|
- |
|
| Wright Timothy |
Director |
– • – |
2020-06-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,338 |
53,876 |
|
- |
|
| Wiinberg Ulf |
Director |
– • – |
2020-06-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,338 |
82,210 |
|
- |
|
| Jeynes-Ellis Allison M |
Director |
– • – |
2020-06-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,338 |
49,323 |
|
- |
|
186 Records found
|
|
Page 3 of 8 |
|
|
